Zydus Cadila has received the final approval from the USFDA to market lsosorbide Dinitrate
Tablets USP (US RLD Isordil Tablet) in the strengths ofS mg, 10 mg, 20 mg, 30 mg and 40
mg. The drug is used to prevent attacks of chest pain (angina). lt dilates (widens) blood vessels,
making it easier for blood to flow through them and easier for the heart to pump. It will be
manufactured at the group's formulations manufacturing facility at Baddi.
The group also received the final approval for Desonide Cream (US RLD Desonide Cream), 0.05%. The drug is a mild corticosteroid, used to treat a variety of skin conditions (e.g., eczema, dermatitis, allergies, rash) to reduce swelling, itching and redness that can occur in these types of conditions. It will be manufactured at the group's Topical manufacturing facility at Ahmedabad.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
